Arnon Chait, PhD, MBA - Chief Executive Officer
Dr. Chait has 25 years of experience at NASA, Analiza, and three other companies. He has co-founded and led revenue based companies in biotech, contract research organizations, and opto-electronics for 15 years. His training and experience covers physics, engineering and biosciences over the past two decades. Dr. Chait has been the founder of an interdisciplinary lab at NASA, has held several academic positions at leading universities, including Tufts and Case Western Reserve University, has extensively published in multiple fields, and is the co-inventor of multiple patents. Arnon has also been the co-founder of two additional companies in the fields of structural genomics and opto-electronics. Dr. Chait has lead revenue-based biotech companies for the past 18 years, successfully navigating commercial endeavors performing contract drug discovery research for the largest (and smallest) pharmaceutical companies for the past dozen of years, developing multiple large impact technologies in life sciences, and exiting through sale of IP in specific fields.
Boris Zaslavsky, PhD, DSC - Chief Scientific Officer
Dr. Zaslavsky has over 30 years of scientific/technical experience. He is the co-founder and chief scientific officer of Cleveland Diagnostics, Inc., and previously of Analiza, Inc. and AnalizaDx, LLC. Dr. Zaslavsky is a bioanalytical chemist with over three decades of experience, beginning at the Russian Academy of Science in Moscow, where he eventually received his Doctor of Science degree, and in the U.S. at Cornell Medical College, Argonne National Lab, and finally at Analiza, AnalizaDx, and currently at Cleveland Diagnostics, where he leads the scientific development of new cancer tests. Dr. Zaslavsky is the developer of the scientific methodology underlying Cleveland Diagnostics analytical and clinical applications. He is the author of over 140 publications, is a co-inventor of multiple patents, and is the author of the definitive book in the field.
Mark Stovsky, MD, MBA, FACS - Chief Medical Officer
Mark Stovsky MD MBA FACS currently serves as Senior Director - Emerging Business at Cleveland Clinic Ventures as well as a Staff Urologist in the Cleveland Clinic Glickman Urological and Kidney Institute and an Associate Professor of Surgery (Urology) in the CCF Lerner School of Medicine.
Prior to joining Cleveland Clinic and Innovations, Mark was an attending urologist at University Hospitals Case Medical Center where he served as Director of the Men's Health and Genitourinary Stone Center and Urology Institute Quality Officer as well as Chief of the Division of Urology and Medical Director for Urology Services at UH Richmond Medical Center. Dr. Stovsky’s areas of clinical expertise including BPH/male voiding dysfunction, prostate cancer and urinary tract stone disease. Dr. Stovsky completed his urology residency training at University Hospitals Case Medical Center in Cleveland, Ohio. Dr. Stovsky's primary research interest is in the area of diagnostic biomarkers for cancer and other diseases and medical economics.
Dr. Stovsky has an extensive business background in new venture development as well as private equity and life science consulting including transaction analysis, due diligence and predictive modeling for health care & biotechnology businesses. Mark’s private equity experience includes transaction analysis for early stage, acquisition and add-on ventures. Dr. Stovsky is CMO of CCF portfolio company Cleveland Diagnostics, Inc. and the CCF board of directors’ representative to eHealth Ventures USA.
Mark currently serves on the board of the American Urological Association (AUA) North Central Section. Dr. Stovsky is currently Treasurer of the NCS. He is Past President of the American Association of Clinical Urologists, the Cleveland Urological Society and the Ohio Urological Society as well as a past board member of UROPAC and the Academy of Medicine of Cleveland/Northern Ohio Medical Association. Dr. Stovsky completed the AUA Leadership Program (2012 - 2013 class). He has also been honored with selection to Castle Connolly Top Doctors (2016 - present) and Best Doctors in America (2010 - present).
Mark has also served on the boards of American Friends of Magen David Adom (Cleveland Chapter - Israel Red Cross) and Park Synagogue.
Dr. Stovsky earned undergraduate and medical degrees from Northwestern. He also holds an MBA (strategic planning) from the Katz Graduate School of Business at the University of Pittsburgh where he was elected to Beta Gamma Sigma.
Joseph Briggman, PhD - Chief Commercial Officer
Dr. Briggman has more than 30 years of experience in diagnostics development and commercialization at multiple companies. He has led teams in the development, regulatory, and distribution of diagnostics technologies. Prior to joining Cleveland Diagnostics, Dr. Briggman was the global product manager of women's health at Alere, Inc. In this role, he managed 36 diagnostic tests for pregnancy, PROM, preterm delivery, sexually transmitted infections, celiac disease, and osteoporosis, which accounted for $80 Million in annual revenue. Dr. Briggman was also the director of oncology at Alere, where he played a critical role in business development, traditional marketing, and product development resulting in annual sales around $20 million. He obtained a BS from La Salle University, a PhD from the University of Pittsburgh School of Medicine, and a postdoctoral fellowship in the department of pathology from the Medical University of South Carolina.
Board of Directors
Tim Longville, C.P.A., C.M.A., C.G.M.A.
Tim Longville is the Executive Director of Corporate Accounting for the Cleveland Clinic. In this role, Tim is responsible for external Financial Reporting, Treasury Services, Accounts Payable, Payroll, Revenue Reimbursement, Capital and Expenditures, Research Compliance and Accounting, and Internal Control Efficiencies for the organization. Tim has 25 years of experience with the Cleveland Clinic Finance Division, and as a graduate of John Carroll University he received a Bachelor of Science in Business Administration with a major in Accounting. Tim is a member of the Boards of Medina Hospital, Finance Committee for Medina Hospital, Center for Health Affairs, Cleveland Diagnostics, Audit Committee for Cleveland Diagnostics, Tatara Vascular LLC, Audit Committee for Cuyahoga Arts and Culture and Treasurer for various not for profits in Northeast Ohio. He has been a member of the American Institute of Certified Public Accountants, Institute of Management Accountants, Ohio Society of Certified Public Accountants and Healthcare Financial Management Association. The Cleveland Clinic Foundation (System) is a nonprofit, tax exempt, Ohio corporation organized and operated to provide medical and hospital care, medical research and education. The System is the leading provider of healthcare services in Northeast Ohio. As of December 31, 2016, the System operates 14 hospitals with approximately 3,900 staffed beds and employees over 51,000 individuals.
Arnon Chait, PhD, MBA
Ben Bronstein, M.D., Chairman
Ben Bronstein is the Executive Vice President of Clinical Development at Aclaris Therapeutics, Inc. (NASDAQ:ACRS). He has 25 years of experience as a founder, executive, and investor in the life sciences industry. In addition to his role at Aclaris, he is the interim Chief Medical Officer at Sentien Biotechnologies, Inc. Prior to joining Sentien, he served as the Chief Medical Officer at Stealth BioTherapeutics. Ben has founded or held senior management positions at several venture-backed life science firms, including BioSurface Technology (regenerative medicine), Peptimmune (immunotherapeutics), Vidus Ocular (glaucoma device), Neuron Systems (dry AMD) and as a Vice President of R&D at OPKO Health (NYSE:OPK; a diversified health products company). He has, as well, been an investor in life science companies as a Managing Director at Zero Stage Capital and as Senior Vice President at Access BridgeGap Ventures, the life science investment unit of Access Industries, Inc. A board certified pathologist, Ben began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School. He is also a member of the Scientific Advisory Committee of the Daedalus Fund for Innovation at Weill Cornell Medical College.
Rivki Stern has 25 years of entrepreneurial, financial, international management and business development experience as executive and consultant. A CPA, Rivki served as CEO and CFO of global corporations, positioned in US, Europe and Asia. She is a strategic advisor to the Israeli government and to various innovation accelerator programs around the country. Rivki is a member of the prestigious Israeli Government's "Director Team", and sits on several boards of life-sciences companies. She co-founded social enterprises and non-profit organizations and is consultant to international NGOs.